Key Takeaways
- Volume-led 14% revenue growth, but pricing drag persists: Highest-ever quarterly revenue of ₹198.6 crores came from a 33% volume surge, yet subdued pricing and auto-ancillary margin compromise kept the quarter grounded.
- 40% FY26 growth guidance reaffirmed with conviction: Management is "very confident" of delivering at least 40% revenue growth this year, backed by order visibility and ramp-up, even after absorbing recent tariff turmoil into its assumptions.
- Margins held to a disciplined band, not chasing expansion: EBITDA margin guidance stays at 17–19% for FY26; the geopolitical environment makes this a year to hold business, not stretch for higher margins.
- Pakhajan plant is the FY27 story, not FY26: The ₹75 crores capacity expansion commissions by January/February, but revenue and utilization benefits only begin in Q1 FY27, with a target of 70–80% utilization by Q4 FY26.
- What to watch next quarter: Whether pricing stabilization converts to actual price recovery, the pace of inventory reduction from 190 days toward the sub-150-day target, and any tariff-policy clarity that unlocks the pricing-power conversation management deferred.
Revenue Growth & Volume Dynamics
- Volume engine running hot: 33% volume growth drove the 14% YoY revenue increase, demonstrating robust underlying demand even as realizations stayed weak.
- Pricing environment stabilizing: After a year-long correction, management sees clear signs of price stabilization, which bodes well for coming quarters.
- Export share climbing toward 70%: Exports already at 67% of revenue and expected to grow further, with market-share gains coming from Western-world customers. Domestic growth is slower, held back by cheap imports.
- China derisking tailwind: The company is receiving more client requests to derisk supply chains away from China, a structural demand driver that plays to Yasho's positioning.
- Seasonal pattern intact: Q1 is typically slow; Q3 and Q4 are historically strong quarters, so the growth trajectory should steepen through the year.
Parag Jhaveri: "When we are talking, yes, I think we talk 40% guidance is very much with the current market trend only. So we are very confident despite recent turmoil in the tariff statement, we are still confident that we'll be able to achieve this 40% growth, at least 40% growth."
Margin Structure & Trade-offs
- Gross margin normalizing, not deteriorating: Gross margins peaked at ~45% in Sep/Dec quarters on exceptional one-time demand for key performance chemicals; the return to ~40% sits within the guided 38–40% range and is not a structural decline.
- Auto-ancillary pressure forced a margin compromise: One part of the industrial segment, serving lubricants, rubber, performance chemicals and coatings, saw the company sacrifice margin to retain market share amid auto-industry turmoil.
- Raw-material vs finished-good asymmetry: Raw material costs declined in some cases, but finished-good price competition was more intense due to the global slowdown, squeezing the spread.
- Inventory-loss risk contained: Some inventory loss occurs from price drops, but management describes it as "very minor," with renegotiation happening quarterly or semi-annually with customers.
- No margin-expansion ambition this year: The geopolitical situation makes this a year to protect business volumes, not to push EBITDA beyond 19%.
Parag Jhaveri: "currently, the geopolitical situation that we try to hold on our business rather to go for a higher margin. So currently, that's not the situation where we said that, yes, we'll be able to increase our EBITDA beyond 19%."
Pakhajan Ramp-Up & Capacity Expansion
- Three of four planned products commissioned and approved: The fourth product should commission by end of this year; all three commissioned products have received customer approvals and two are already seeing good utilization with capacity being increased.
- Utilization above 50%, targeting 70–80% by Q4 FY26: Management is actively working to enhance utilization through deeper customer engagement and potential global partner collaboration, with results expected in coming quarters.
- ₹75 crores capex is a FY27 revenue event: The capacity expansion commissions by January/February, but actual utilization and revenue generation begin only in Q1 FY27, with expected incremental revenue of ₹200 crores-plus.
- Returns target of 3x to 4x on assets: Management is looking to return to the 3x–4x fixed-asset-turnover range it enjoyed before 2024, with the 3x target by FY27 unchanged.
Balance Sheet & Working Capital
- Inventory reduction underway but structurally challenged: Inventory fell from over 200 days to 190 days in Q1, with a target below 150 days. However, customers now demand material on call without longer lead times, forcing the company to carry unusually high inventory.
- Debt repayment progressing: Some debt was repaid in the current quarter, with further repayments of about ₹9 crores starting November 2025. The long-term comfort zone for debt-to-EBITDA is 2.5x, with a target to bring it below 3x by FY27.
- ROCE improvement path: Better capacity utilization and working-capital reduction are the twin levers management is pulling to improve return ratios.
Parag Jhaveri: "Good inventory should be the 110 to 120 days, but we need to bring it back. We are growing. We need to hold inventory. Currently, the customers are asking material on call. They don't give you the longer lead time. So, because of that, we need to carry unusually high inventory, and we hope the situation change sooner."
Tariffs, Pricing Power & Competitive Positioning
- Tariff pass-through decision deferred: Management declined to answer whether incremental tariffs would be passed to customers, citing confusion and the need to wait for policy clarity expected within a week to ten days.
- US exposure capped at ~25%: The US will remain about a quarter of revenue; management does not see the share growing beyond that level.
- Cost-competitive versus Europe and the US, challenged versus China in spots: The company is quite competitive against Western producers but faces pricing challenges from China in certain segments.
- Market-share ambition is modest in absolute terms: Yasho is targeting only about 0.2% of the global addressable market, aspiring to reach ₹900–1,000 crores this year, a "very, very nominal market share."
Parag Jhaveri: "We are trying to gain only about 0.2% of that. We aspire to go to INR900 crores to INR1,000 crores this year. So we are not looking at a very huge market share, very, very nominal market share."
R&D, Supply Chain & Strategic Initiatives
- R&D lab on track for October 2025: The state-of-the-art facility works on dual tracks: improving existing processes to minimize waste, and developing new chemistry for the industrial segment across both short-term and long-term projects.
- Local sourcing push to cut import dependency: Management has identified 2–3 suppliers who can produce chemistries not yet made domestically; the large inventory carried today partly reflects import-logistics challenges this initiative aims to solve.
- Supply-chain risk diversified: Very few products depend on a single geography; the majority have multiple sources across Asia, Europe, North America and South America.
- FY27 capex still on the drawing board: No plan yet for next year's capex; management will return with details in the April 2026 call.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | At least 40% YoY growth in FY26 | FY26 full year |
| EBITDA margin | Hold in 17–19% range; not exceeding 19% | FY26 full year |
| Gross margin | 40% plus/minus 1–2% (raw material to finished goods) | Ongoing |
| Fixed asset turnover | 3x | By FY27 |
| Net working capital (inventory days) | Reduce from 190 days to below 150 days | Not specified |
| Debt-to-EBITDA | Below 3x | By FY27 |
| Pakhajan utilization | 70–80% | By Q4 FY26 |
| Capacity expansion (₹75 cr) commissioning | Commission by Jan/Feb; revenue from Q1 FY27 | Jan/Feb 2026 |
| R&D laboratory completion | State-of-the-art facility operational | October 2025 |
| Fourth Pakhajan product commissioning | Commission the remaining product | By end of 2025 |
| Long-term debt-to-EBITDA | Comfortable at 2.5x | Long-term |
| Export revenue share | Grow to 70% of total revenue | Going forward |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Revenue | ₹198.6 cr, highest ever quarterly revenue, +14% YoY |
| Volume growth | 33% YoY |
| Standalone EBITDA margin | 18.01% |
| Consolidated EBITDA margin | 17.02% (corrected from 17.05% stated on call) |
| Gross margin | ~40%, down from peak of ~45% in Sep/Dec quarters; guided range 38% to 40% |
| Industrial Chemicals EBITDA margin | More than 20% |
| Consumer Chemicals EBITDA margin | Single digit |
| Industrial Chemicals revenue share | 87% of total revenue |
| Consumer Chemicals revenue share | 13% of total revenue |
| Revenue growth guidance for FY26 | At least 40%, based on current market trends |
| Pakhajan plant utilization | Over 50% during the quarter, more than about 55% |
| Vapi plant utilization | 70% to 75% |
| Capex incurred in Q1 FY26 | ₹30 cr out of planned annual capex of ₹100 cr |
| FY26 planned capex | ₹100 cr, comprising ₹75 cr for plant and machinery capacity increase and ₹25 cr for R&D facility |
| Net working capital (inventory days) | 190 days, down from more than 200 days; target below 150 days |
| US revenue share | 25% of total revenue |
| Auto and auto ancillary revenue contribution | ~25% |
| Revenue per kg (aggregate) | ~₹400 per kilo |
| Average selling price per kg (Pakhajan) | ~₹200 per kilo |
| Long-term borrowing | ₹333.28 cr (corrected from ₹280 cr stated on call) |
| Short-term borrowing | ₹210.98 cr (corrected from ₹100 cr stated on call) |
| Debt-to-EBITDA target | Below 3 by FY27; comfortable range of 2.5x in the long-term |
| Tax rate | ~30% (29-point-something) |
| Export revenue share expectation | 70% of total revenue going forward, up from 67% |
| R&D facility completion timeline | October 2025 |
| Fixed asset turnover target | 3x by FY27 |